Single dose intranasal immunization with ISCOMATRIX™ vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract

Vaccine

Volumn 27, Issue 18, 2009, Pages 2475-2482

  Sanders, Megan T ^a   Deliyannis, Georgia ^a   Pearse, Martin J ^b   McNamara, Michael K ^b   Brown, Lorena E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CSL LIMITED   (Australia)

Author keywords

Adjuvant; Influenza; Vaccine delivery

Indexed keywords

ANTIBODY; ANTIGEN; INFLUENZA VACCINE; ISCOMATRIX; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CLEARANCE; CONTROLLED STUDY; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; LOWER RESPIRATORY TRACT; LUNG FLUID; MOUSE; NONHUMAN; NOSE MUCUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SALIVA; SINGLE DRUG DOSE; VAGINA DISCHARGE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHOLESTEROL; DRUG COMBINATIONS; IMMUNIZATION; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; PHOSPHOLIPIDS; SAPONINS;

EID: 62749200399     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.054     Document Type: Article

References (49)

1. Brokstad K.A., Eriksson J.C., Cox R.J., Tynning T., Olofsson J., Jonsson R., et al. Parenteral vaccination against influenza does not induce a local antigen-specific immune response in the nasal mucosa. J Infect Dis 185 7 (2002) 878-884
2. Persson C.G., Erjefalt J.S., Greiff L., Erjefalt I., Korsgren M., Linden M., et al. Contribution of plasma-derived molecules to mucosal immune defence, disease and repair in the airways. Scand J Immunol 47 4 (1998) 302-313
3. Ramphal R., Cogliano R.C., Shands Jr. J.W., and Small Jr. P.A. Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis. Infect Immun 25 3 (1979) 992-997
4. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., and Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21 23 (2003) 3212-3218
5. Giudice E.L., and Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 58 1 (2006) 68-89
6. O'Hagan D.T., and Rappuoli R. Novel approaches to vaccine delivery. Pharmaceut Res 21 9 (2004) 1519-1530
7. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 10 2 (1992) 75-88
8. Elson C.O., and Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 133 6 (1984) 2892-2897
9. Tamura S., Samegai Y., Kurata H., Nagamine T., Aizawa C., and Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6 5 (1988) 409-413
10. Tamura S., Yamanaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12 5 (1994) 419-426
11. Hashigucci K., Ogawa H., Ishidate T., Yamashita R., Kamiya H., Watanabe K., et al. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14 2 (1996) 113-119
12. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., and McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 20 19-20 (2002) 2431-2438
13. van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 9 (2000) 4778-4782
14. Sjolander S., Drane D., Davis R., Beezum L., Pearse M., and Cox J. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine 19 28-29 (2001) 4072-4080
15. Morein B., Sundquist B., Hoglund S., Dalsgaard K., and Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308 5958 (1984) 457-460
16. Sanders M.T., Brown L.E., Deliyannis G., and Pearse M.J. ISCOM-based vaccines: the second decade. Immunol Cell Biol 83 2 (2005) 119-128
17. Davis I.D., Chen W., Jackson H., Parente P., Shackleton M., Hopkins W., et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 101 29 (2004) 10697-10702
18. Ennis F.A., Cruz J., Jameson J., Klein M., Burt D., and Thipphawong J. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS). Virology 259 2 (1999) 256-261
19. Frazer I.H., Quinn M., Nicklin J.L., Tan J., Perrin L.C., Ng P., et al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23 2 (2004) 172-181
20. Rimmelzwaan G.F., Nieuwkoop N., Brandenburg A., Sutter G., Beyer W.E., Maher D., et al. A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. Vaccine 19 9-10 (2001) 1180-1187
21. Coulter A., Harris R., Davis R., Drane D., Cox J., Ryan D., et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21 9-10 (2003) 946-949
22. Deliyannis G., Jackson D.C., Dyer W., Bates J., Coulter A., Harling-McNabb L., et al. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine 16 20 (1998) 2058-2068
23. Lovgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol 27 2 (1988) 241-245
24. Pearse M.J., and Drane D. ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses. Vaccine 22 19 (2004) 2391-2395
25. Yetter R.A., Lehrer S., Ramphal R., and Small Jr. P.A. Outcome of influenza infection: effect of site of initial infection and heterotypic immunity. Infect Immun 29 2 (1980) 654-662
26. Novak M., Moldoveanu Z., Schafer D.P., Mestecky J., and Compans R.W. Murine model for evaluation of protective immunity to influenza virus. Vaccine 11 1 (1993) 55-60
27. Iida T., and Bang F.B. Infection of the upper respiratory tract of mice with influenza A virus. Am J Hyg 77 (1963) 169-176
28. Ugozzoli M., O'Hagan D.T., and Ott G.S. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses. Immunology 93 4 (1998) 563-571
29. Bizanov G., Janakova L., Knapstad S.E., Karlstad T., Bakke H., Haugen I.L., et al. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand J Immunol 61 6 (2005) 503-510
30. Janakova L., Bakke H., Haugen I.L., Berstad A.K., Hoiby E.A., Aaberge I.S., et al. Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines. Infect Immun 70 10 (2002) 5479-5484
31. Visweswaraiah A., Novotny L.A., Hjemdahl-Monsen E.J., Bakaletz L.O., and Thanavala Y. Tracking the tissue distribution of marker dye following intranasal delivery in mice and chinchillas: a multifactorial analysis of parameters affecting nasal retention. Vaccine 20 25-26 (2002) 3209-3220
32. Metzler B., Anderton S.M., Manickasingham S.P., and Wraith D.C. Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide. Immunol Invest 29 1 (2000) 61-70
33. Eyles J.E., Bramwell V.W., Williamson E.D., and Alpar H.O. Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. Vaccine 19 32 (2001) 4732-4742
34. Drane D.P., and Pearse M.J. The ISCOMATRIX adjuvant. In: Schijns N., and O'Hagan D. (Eds). Immunpotentiators in modern vaccines (2006), Elsevier, Oxford 191-216
35. Coulter A., Wong T.Y., Drane D., Bates J., Macfarlan R., and Cox J. Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines. Vaccine 16 11-12 (1998) 1243-1253
36. Jackson D.C., Tang X.L., Brown L.E., Murray J.M., White D.O., and Tregear G.W. Antigenic determinants of influenza virus hemagglutinin. XII. The epitopes of a synthetic peptide representing the C-terminus of HA1. Virology 155 2 (1986) 625-632
37. Tannock G.A., Paul J.A., and Barry R.D. Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun 43 2 (1984) 457-462
38. Eldridge J.H., Gilley R.M., Staas J.K., Moldoveanu Z., Meulbroek J.A., and Tice T.R. Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol 146 (1989) 59-66
39. Kuper C.F., Koornstra P.J., Hameleers D.M., Biewenga J., Spit B.J., Duijvestijn A.M., et al. The role of nasopharyngeal lymphoid tissue. Immunol Today 13 6 (1992) 219-224
40. Spit B.J., Hendriksen E.G., Bruijntjes J.P., and Kuper C.F. Nasal lymphoid tissue in the rat. Cell Tissue Res 255 1 (1989) 193-198
41. Bienenstock J., and McDermott M.R. Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 206 (2005) 22-31
42. Moyron-Quiroz J.E., Rangel-Moreno J., Kusser K., Hartson L., Sprague F., Goodrich S., et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 10 9 (2004) 927-934
43. Owens S.L., Osebold J.W., and Zee Y.C. Dynamics of B-lymphocytes in the lungs of mice exposed to aerosolized influenza virus. Infect Immun 33 1 (1981) 231-238
44. Jones P.D., and Ada G.L. Influenza virus-specific antibody-secreting cells in the murine lung during primary influenza virus infection. J Virol 60 2 (1986) 614-619
45. Tamura S., Iwasaki T., Thompson A.H., Asanuma H., Chen Z., Suzuki Y., et al. Antibody-forming cells in the nasal-associated lymphoid tissue during primary influenza virus infection. J Gen Virol 79 Pt 2 (1998) 291-299
46. Rharbaoui F., Bruder D., Vidakovic M., Ebensen T., Buer J., and Guzman C.A. Characterization of a B220+ lymphoid cell subpopulation with immune modulatory functions in nasal-associated lymphoid tissues. J Immunol 174 3 (2005) 1317-1324
47. Bracci L., Canini I., Puzelli S., Sestili P., Venditti M., Spada M., et al. Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. Vaccine 23 23 (2005) 2994-3004
48. Jones P.D., Tha Hla R., Morein B., Lovgren K., and Ada G.L. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms). Scand J Immunol 27 6 (1988) 645-652
49. McDermott M.R., and Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 122 5 (1979) 1892-1898